Amylyx Pharmaceuticals reported net income of -$43.64M for the quarter ended Jun 2026. This income statement covers 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 6.80M | 7.02M | 57.86M | 58.53M | 58.53M | 66.51M | 67.10M | 67.35M | 67.51M | 67.71M | 67.98M | 68.08M | 68.55M | 68.63M | 89.08M | 89.16M | 109.77M | 109.88M | 111.03M | 111.37M | ||
| Revenue & cost | ||||||||||||||||||||||
| Revenue | 0.28M | 0.34M | 21.89M | 71.43M | 98.22M | 102.69M | 108.45M | 88.64M | 1.02M | 0.42M | -0.64M | |||||||||||
| Gross Profit | 0.17M | 19.06M | 66.14M | 92.64M | 97.47M | 99.09M | 82.70M | 1.01M | 0.42M | -0.64M | ||||||||||||
| Operating items | ||||||||||||||||||||||
| Research & DevelopmentR&D | 12.85M | 13.39M | 21.46M | 24.26M | 24.91M | 22.81M | 24.19M | 29.04M | 30.04M | 44.91M | 36.61M | 23.35M | 21.24M | 22.89M | 22.12M | 27.22M | 19.86M | 21.21M | 27.61M | 23.77M | ||
| Selling, General & AdministrativeSG&A | 10.35M | 14.92M | 26.35M | 29.99M | 29.94M | 40.84M | 44.01M | 43.39M | 48.72M | 52.24M | 57.76M | 21.65M | 17.83M | 17.10M | 15.68M | 15.64M | 16.17M | 15.39M | 16.17M | 21.93M | ||
| Restructuring CostsRestructuring | 22.85M | |||||||||||||||||||||
| Other Operating ExpensesOther Opex | 0.17M | 2.82M | 5.28M | 5.58M | 5.22M | 9.36M | 116.41M | 7.42M | 37.01M | |||||||||||||
| Operating ExpensesOpex | 23.20M | 28.32M | 47.81M | 54.25M | 55.03M | 66.48M | 73.48M | 78.02M | 83.97M | 106.52M | 210.77M | 75.26M | 76.08M | 39.99M | 37.80M | 42.86M | 36.03M | 36.60M | 43.78M | 45.69M | ||
| Operating IncomeOp. Inc | -22.92M | -28.32M | -47.81M | -54.25M | -54.68M | -44.59M | -2.05M | 20.20M | 18.72M | 1.93M | -122.13M | -76.29M | -75.66M | -40.65M | -37.80M | -42.86M | -36.03M | -36.60M | -43.78M | -45.69M | ||
| EBIT | -22.92M | -28.32M | -47.81M | -54.25M | -54.68M | -44.59M | -2.05M | 20.20M | 18.72M | 1.93M | -122.13M | -76.29M | -75.66M | -40.65M | -37.80M | -42.86M | -36.03M | -36.60M | -43.78M | -45.69M | ||
| Non-operating items | ||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 0.03M | 0.13M | 0.40M | 0.60M | 3.16M | 3.72M | 3.89M | 4.18M | 4.37M | 4.33M | 4.07M | 3.10M | 2.32M | 2.23M | 1.96M | 1.82M | 3.29M | 2.57M | 2.32M | ||
| Other Non Operating IncomeOther Non Op Inc. | -0.23M | -0.06M | -0.02M | -0.04M | 0.20M | -0.69M | -0.26M | -0.08M | -0.49M | 0.17M | -0.75M | -0.48M | -0.14M | 8.42M | -0.34M | -0.55M | -0.18M | 3.79M | -0.07M | -0.05M | ||
| Non Operating IncomeNon Op. Inc. | -0.22M | -0.03M | 0.11M | 0.36M | 0.80M | 2.47M | 3.46M | 3.81M | 3.69M | 4.54M | 3.58M | 3.59M | 2.96M | 2.47M | 1.90M | 1.41M | 1.64M | 3.65M | 2.50M | 2.27M | ||
| Net income details | ||||||||||||||||||||||
| EBT | -23.14M | -28.34M | -47.70M | -53.89M | -53.88M | -43.23M | 1.40M | 24.01M | 22.41M | 6.48M | -118.55M | -72.70M | -72.70M | -38.18M | -35.91M | -41.44M | -34.39M | -32.95M | -41.21M | -43.37M | ||
| Tax ProvisionsTaxes | 0.15M | 0.20M | -0.12M | 0.57M | -0.17M | 1.93M | 1.52M | 1.97M | 0.24M | -63.69M | -30.38M | |||||||||||
| Profit After TaxPAT | -23.14M | -28.34M | -47.85M | -54.07M | -53.76M | -42.70M | 1.57M | 22.07M | 20.89M | 4.73M | -118.79M | -72.70M | -72.70M | -37.55M | -35.91M | -41.44M | -34.39M | -33.00M | -41.28M | -43.64M | ||
| Income from Continuing OperationsIncome (Continuing) | -23.14M | -28.34M | -47.85M | -54.09M | -53.76M | -43.80M | 1.57M | 22.07M | 20.89M | 4.51M | -118.79M | -72.70M | -72.70M | 25.51M | -35.91M | -41.44M | -34.39M | -2.57M | -41.21M | -43.37M | ||
| Consolidated Net IncomeConsol Net Inc. | -23.14M | -28.34M | -47.85M | -54.09M | -53.76M | -43.80M | 1.57M | 22.07M | 20.89M | 4.51M | -118.79M | -72.70M | -72.70M | 25.51M | -35.91M | -41.44M | -34.39M | -2.57M | -41.21M | -43.37M | ||
| Income towards Parent CompanyParent Net Inc | -23.14M | -28.34M | -47.85M | -54.09M | -53.76M | -43.80M | 1.57M | 22.07M | 20.89M | 4.51M | -118.79M | -72.70M | -72.70M | 25.51M | -35.91M | -41.44M | -34.39M | -2.57M | -41.21M | -43.37M | ||
| Net Income towards Common StockholdersNet Income | -23.14M | -28.34M | -47.85M | -54.09M | -53.76M | -43.80M | 1.57M | 22.07M | 20.89M | 4.51M | -118.79M | -72.70M | -72.70M | 25.51M | -35.91M | -41.44M | -34.39M | -2.57M | -41.21M | -43.37M | ||
| Additional items | ||||||||||||||||||||||
| EPS (Basic) | -3.42 | -4.30 | -0.93 | -0.93 | -0.92 | -0.75 | 0.02 | 0.33 | 0.31 | 0.07 | -1.75 | -1.07 | -1.07 | 0.37 | -0.42 | -0.46 | -0.37 | -0.03 | -0.37 | -0.39 | ||
| EPS (Diluted) | -3.42 | -4.30 | -0.93 | -0.93 | -0.92 | -0.75 | 0.02 | 0.31 | 0.30 | 0.06 | -1.75 | -1.07 | -1.07 | 0.37 | -0.42 | -0.46 | -0.37 | -0.03 | -0.37 | -0.39 | ||
| Shares Outstanding | 6.76M | 6.59M | 51.60M | 58.28M | 58.53M | 58.50M | 66.72M | 67.23M | 67.41M | 67.23M | 67.85M | 68.02M | 68.09M | 68.14M | 85.70M | 89.14M | 93.33M | 94.57M | 110.56M | 111.20M | ||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 6.76M | 6.59M | 51.60M | 58.28M | 58.53M | 58.50M | 70.86M | 70.13M | 69.75M | 69.99M | 67.85M | 68.02M | 68.09M | 68.14M | 85.70M | 89.14M | 93.33M | 94.57M | 110.56M | 111.20M | ||
| EBITDA | -22.92M | -28.32M | -47.81M | -54.25M | -54.68M | -44.59M | -2.05M | 20.20M | 18.72M | 1.93M | -122.13M | -76.29M | -75.66M | -40.65M | -37.80M | -42.86M | -36.03M | -36.60M | -43.78M | -45.69M | ||
| Tax Rate | -0.31 | -0.37 | 0.23 | -1.33 | -12.12 | 8.05 | 6.77 | 30.40 | -0.20 | 166.81 | 92.20 |